Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.
Phase of Trial: Phase 0
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Durvalumab (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Pharmacodynamics; Proof of concept
- 13 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 13 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
- 13 Sep 2017 Status changed from active, no longer recruiting to recruiting.